BUZZ-Regeneron Pharma gains as BofA upgrades rating
I'm PortAI, I can summarize articles.
Shares of drugmaker Regeneron Pharmaceuticalsup 3.7% at $805.32BofA Global Research upgrades rating to “buy” from “underperform”; raises PT to $860 from $627New PT represents ~11% upside to stock’s last closeBrokerage views newer version of eye drug Eylea SD to be more positive in light of label updates“We see meaningful upside from Dupixent and late-stage pipeline assets entering 2026” — BofAStock up 8.4% in 2025
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments